drugset

drugset / Trial / NCT05011851

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

NCT05011851 ↗

Phase 2 Completed 17 enrolled Neuren Pharmaceuticals Limited

NaSingle-groupOpen-labelTreatment

Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome

Timeline

Start: 2022-07-12
Primary completion: 2024-05-13
Completion: 2024-07-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NNZ-2591	Small molecule	50 mg/ml	Oral

Indications